ibrutinib
Showing 1 - 25 of 220
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Small Lymphocytic Lymphoma
- Ibrutinib
- Venetoclax
- (no location specified)
Jul 19, 2023
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Nemtabrutinib
- +2 more
- (no location specified)
Nov 22, 2023
Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))
Active, not recruiting
- Glioblastoma
- Ibrutinib
- +2 more
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023
Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
-
Augusta, GeorgiaAugusta University, Georgia Cancer Center
Dec 16, 2022
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
Recruiting
- PCNSL
- Ibrutinib
-
Milan, ItalyOspedale San Raffaele
Mar 13, 2023
Chronic GVHD Trial in Bethesda, Saint Louis (Ibrutinib)
Recruiting
- Chronic GVHD
- Ibrutinib
-
Bethesda, Maryland
- +1 more
Jan 26, 2023
Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in
Active, not recruiting
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- +2 more
- Ibrutinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 20, 2023
Mantle Cell Lymphoma Trial in Houston (Ibrutinib)
Recruiting
- Mantle Cell Lymphoma
- Ibrutinib
-
Houston, TexasM D Anderson Cancer Center
Nov 1, 2022
Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)
Completed
- Waldenstrom's Macroglobulinemia
- Ibrutinib
-
Boston, Massachusetts
- +1 more
Dec 5, 2022
CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)
Recruiting
- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- +2 more
- Ibrutinib
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)
Active, not recruiting
- T-cell Lymphoma
- Relapsed and Refractory T-cell Lymphoma
- Ibrutinib
-
New York, New York
- +1 more
Nov 8, 2022
Graft Vs Host Disease Trial in Atlanta (Rituximab, Ibrutinib)
Recruiting
- Graft Vs Host Disease
- Rituximab
- Ibrutinib
-
Atlanta, GeorgiaNorthside Hospital
Oct 19, 2022
Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)
Terminated
- Diffuse Large B-cell Lymphoma
- Tisagenlecleucel
- Ibrutinib
-
Tampa, Florida
- +1 more
Jan 27, 2023
Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)
Active, not recruiting
- Waldenstrom Macroglobulinemia
- Ibrutinib
-
Changchun, China
- +5 more
Jan 27, 2023
CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)
Recruiting
- Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- TEDD-R
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Prostate Cancer Trial in San Francisco, Saint Louis (Ibrutinib, Blood samples for PSA and immune assays, Radical prostatectomy)
Recruiting
- Prostate Cancer
- Ibrutinib
- +2 more
-
San Francisco, California
- +1 more
Aug 15, 2022
Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Ulocuplumab
- Ibrutinib
-
Boston, MassachusettsDana Farber Cancer Institute
Jun 20, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 13, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Ibrutinib
- Pembrolizumab
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Aug 22, 2022